Improved neuroimaging and molecular markers of Alzheimer disease (AD) have aided diagnosis of AD in the very early stages, and have facilitated differential diagnosis between AD and other neurodegenerative disorders with dementia. The finding that some older individuals can show amyloid-β pathology while remaining cognitively intact raises important questions regarding prevention strategies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Submonolayer biolasers for ultrasensitive biomarker detection
Light: Science & Applications Open Access 06 December 2023
-
A multistart tabu search-based method for feature selection in medical applications
Scientific Reports Open Access 10 October 2023
-
Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease
Nature Medicine Open Access 29 May 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dubois, B. et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 13, 614–629 (2014).
Bentzinger, T. L. et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc. Natl Acad. Sci. USA 110, E4502–E4509 (2013).
Norton, S. et al. Potential for primary prevention of Alzheimer's disease-an analysis of population-based data. Lancet Neurol. 13, 788–794 (2014).
Okamura, N. et al. Non-invasive assessments of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain 137, 1762–1771 (2014).
Chien, D. T. et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J. Alz. Dis. 38, 171–184 (2014).
Maruyama, M. et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to controls. Neuron 79, 1094–1098 (2013).
Fagan, A. M. et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci. Transl. Med. 5, 226ra30 (2014).
Jack, C. R. et al. Age-specific population frequences of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study. Lancet Neurol. 13, 997–1005 (2014).
Crary, J. F. et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128, 755–766 (2014).
Mormino, E. C. et al. Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 71, 1379–1385 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Nordberg, A. Towards early diagnosis in Alzheimer disease. Nat Rev Neurol 11, 69–70 (2015). https://doi.org/10.1038/nrneurol.2014.257
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2014.257
This article is cited by
-
A multistart tabu search-based method for feature selection in medical applications
Scientific Reports (2023)
-
Submonolayer biolasers for ultrasensitive biomarker detection
Light: Science & Applications (2023)
-
Recent Advances in Photoelectrochemical Sensing of Alzheimer’s Biomarkers
BioChip Journal (2023)
-
Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease
Nature Medicine (2023)
-
The fusiform gyrus exhibits an epigenetic signature for Alzheimer’s disease
Clinical Epigenetics (2020)